SCHEMBL13953752

SCHEMBL13953752

CC1CCNC1Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.47
GBA1 P04062 1/20 0.47
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29998378 1.00 POLB (0.47) POLBGBA1NOS1NOS2
SCHEMBL23477650 1.00 POLB (0.47) POLBGBA1NOS1NOS2
SCHEMBL23477733 1.00 POLB (0.47) POLBGBA1NOS1NOS2
SCHEMBL23459137 1.00 POLB (0.47) POLBGBA1NOS1NOS2
SCHEMBL18883042 0.81 NOS1 (0.42) POLBGBA1NOS1NOS2
SCHEMBL18883041 0.81 NOS1 (0.42) POLBGBA1NOS1NOS2
SCHEMBL23255522 0.81 NOS1 (0.42) POLBGBA1NOS1NOS2
SCHEMBL18883048 0.81 NOS1 (0.42) POLBGBA1NOS1NOS2
SCHEMBL18883040 0.81 NOS1 (0.42) POLBGBA1NOS1NOS2
SCHEMBL23477776 0.78 AGL (0.48) POLBGBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4069366-B1 ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION INC (US) 2025-03-19 EP disclosed
US-11685734-B2 ATM kinase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2023-06-27 US disclosed
EP-4069366-A1 ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation, Inc. (US) 2022-10-12 EP disclosed
US-20210188827-A1 ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2021-06-24 US disclosed
WO-2021113506-A1 ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. (US) 2021-06-10 WO disclosed
US-7491731-B2 Crystal structure of liganded cFMS kinase domain SMITHKLINE BEECHAM CORPORATION (US) 2009-02-17 US disclosed
US-20070010540-A1 Crystal structure of liganded cFMS kinase domain SHEWCHUK LISA M 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010540-A1 Crystal structure of liganded cFMS kinase domain FAM20C, FRS2, FRK POLB 2250/4885GBA1 772/4885NOS1 4802/4885
US-11685734-B2 ATM kinase inhibitors and compositions and methods of use thereof ATM, CHEK2, CHEK1 POLB 260/4885GBA1 3258/4885NOS1 2814/4885
US-20210188827-A1 ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF ATM, CHEK2, CHEK1 POLB 260/4885GBA1 3258/4885NOS1 2814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.